A Methionine Allocation Nanoregulator for the Suppression of Cancer Stem Cells and Support to the Immune Cells by Epigenetic Regulation
Advanced Science · 2025
DOI: 10.1002/advs.202415207 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Boyu Su und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory…. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Epigenesis, Genetic, Methionine, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, ZJLab, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Epigenetic dysregulation is prevalent in human cancers, affecting gene expression and metabolic patterns to meet the demands of malignant evolution and abnormal epigenetic processes, and resulting in a protumor immune microenvironment. Tumors require a steady supply of methionine for maintaining epigenetic flexibility, which is the only exogenous precursor of methyl donor S‐adenosylmethionine for methylation, crucial for their resistance to therapies and survival in a nutrient‐deficient microenvironment. Thus, tumor cells upregulate the Lat4 transporter to compete and deprive methionine in the microenvironment, sustaining their malignant phenotypes and also impairing immune cell functions. Addressing this methionine addiction is the key to overcoming drug resistance and improving immune response. Despite the challenge of lacking specific Lat4 inhibitors, an oxaliplatin prodrug crosslinked fluorinated polycation/anti‐Lat4 small interfering RNA complex nanoregulator (AS‐F‐NP) has been designed and developed here. This nanoregulator restricted the greedy methionine uptake of tumor cells by knocking down Lat4, which in turn inhibited the malignant evolution of the tumor while restoring the viability and function of tumor‐infiltrating immune cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, S…
- Department of Digestive Diseases, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350212, China.
- Quzhou Fudan Institute, Quzhou, 324003, China.
ORCID-Profile: Tao Sun
Förderung
- National Natural Science Foundation of China
- ZJLab
- Science and Technology Commission of Shanghai Municipality
- Ministry of Science and Technology of the People's Republic of China
Zitieren
APA
Su, B., Chen, Q., Li, X., Fang, M., Wang, Y., Song, H., You, H., Zhou, Z., Wu, Y., Zhao, Z., Chen, Y., Fan, H., Li, C., Jiang, C., & Sun, T. (2025). A Methionine Allocation Nanoregulator for the Suppression of Cancer Stem Cells and Support to the Immune Cells by Epigenetic Regulation. Advanced Science. https://doi.org/10.1002/advs.202415207
Vancouver
Su B, Chen Q, Li X, Fang M, Wang Y, Song H, et al. A Methionine Allocation Nanoregulator for the Suppression of Cancer Stem Cells and Support to the Immune Cells by Epigenetic Regulation. Advanced Science. 2025. doi:10.1002/advs.202415207
BibTeX
@article{Su2025,
author = {Su, Boyu and Chen, Qinjun and Li, Xuwen and Fang, Mingzhu and Wang, Yu and Song, Haolin and You, Haoyu and Zhou, Zheng and Wu, Yuxing and Zhao, Zhenhao and Chen, Yun and Fan, Hongrui and Li, Chufeng and Jiang, Chen and Sun, Tao},
title = {A Methionine Allocation Nanoregulator for the Suppression of Cancer Stem Cells and Support to the Immune Cells by Epigenetic Regulation},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202415207}
}
EUVIMED